LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
暂无分享，去创建一个
C. Dooms | F. de Marinis | J. Mazières | M. Wislez | Y. Wu | E. Nadal | L. Tho | X. Le | H. Hayashi | E. Smit | J. Raskin | G. Finocchiaro | T.M. Kim | B. Ellers-Lenz | S. Brutlach | S. Adrian | C. Liam | B. Lim | A.M. O'Brate Grupp | N. Karachaliou